|
|||||
|
|
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors |
|
| Authors: | Steven D. Fidanze Dachun Liu Robert A. Mantei Lisa A. Hasvold John K. Pratt George S. Sheppard Le Wang James H. Holms Yujia Dai Ana Aguirre Andrew Bogdan Justin D. Dietrich Jasmina Marjanovic Chang H. Park Charles W. Hutchins Xiaoyu Lin Mai H. Bui Xiaoli Huang Keith F. McDaniel |
| Affiliation: | 1. AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064, United States |
| Abstract: | Novel conformationally constrained BET bromodomain inhibitors have been developed. These inhibitors were optimized in two similar, yet distinct chemical series, the 6-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-ones (A) and the 1-methyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-ones (B). Each series demonstrated excellent activity in binding and cellular assays, and lead compounds from each series demonstrated significant efficacy in in vivo tumor xenograft models. |
| Keywords: | Corresponding authors. |
| 本文献已被 ScienceDirect 等数据库收录！ | |